Behind Thermo Fisher’s Recent Stock Performance



Thermo Fisher Scientific’s stock movement

Thermo Fisher Scientific (TMO) stock was trading at $173.2 on May 30, 2017. The stock had a 50-day moving average of $165.9 and a 200-day moving average of $153.8 as of that day.

TMO is a leading manufacturer of laboratory products and analytical instruments in the US and reported a strong performance in 1Q17, exceeding analysts’ estimates as well as its own company guidance.

On May 30, 2017, TMO stock was trading 0.2% below its 52-week high of $173.6 as of May 23, 2017, and ~24.6% above its 52-week low of $139.1 as of December 1, 2016. The company’s share price has risen ~9% since the release of its fiscal 1Q17 earnings on April 26, 2017.

On May 15, 2017, Thermo Fisher stock gained ~0.5% on the announcement of its acquisition of Patheon.

Article continues below advertisement

Comparisons with industry and market performances

Thermo Fisher stock has returned ~14% in the past 12 months. It has also outperformed the market as represented by the S&P 500 Index, which has returned ~15% during the same period. Notably, the Health Care Select Sector SPDR ETF (XLV) has fallen more than 6.5% in the past 12 months.

TMO’s stock performance can also be compared to the performance of the US medical device sector, which is represented by the iShares US Medical Devices ETF (IHI). Thermo Fisher has returned ~23% on a YTD (year-to-date) basis, as compared to the 7.8% and 20.8% returns generated by the market (SPY) and IHI, respectively.

As of May 30, 2017, peers Becton, Dickinson (BDX), Stryker (SYK), and Baxter (BAX) have generated returns of 12.6%, 27%, and 37%, respectively, over the past 12 months.

For a brief company overview, check out Market Realist’s A Must-Read Company Overview of Thermo Fisher Scientific.


More From Market Realist